Cardiovascular disease risk associated with asthma and respiratory morbidity might be mediated by short-acting β2-agonists

Sarah Appleton, Richard E. Ruffin, David H. Wilson, Anne Taylor, Robert Adams

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Studies examining the asthma-related risks of cardiovascular disease (CVD) events have generally used selected samples or did not control for the effects of β2-agonist use, itself associated with CVD events. Objectives: We assessed the relationship between incident CVD/stroke and asthma and the effect of atopy while controlling for β2-agonist use in a representative adult population cohort free of CVD at baseline. Methods: The North West Adelaide Health Study (stage 1, n = 3812; stage 2, n = 3113) assessed spirometry, anthropometry, atopy, blood pressure, and lipid levels. Questionnaires assessed doctor-diagnosed asthma and CVD (myocardial infarction and angina)/stroke, smoking status, and demographics. Asthma was defined by self-report or FEV1 reversibility. Current short- and long-acting β2-agonist use was identified at follow-up. Results: Results are expressed as odds ratios (ORs) and 95% CIs. By using multivariable logistic regression, after adjustment for risk factors, in female subjects incident CVD/stroke events were associated with asthma (OR, 3.24; 95% CI, 1.55-6.78), with no effect modification by atopy (P for interaction = .61), and with as-required short-acting β2-agonist use (OR, 2.66; 95% CI, 1.06-6.61). In male subjects events were associated with daily cough/sputum (OR, 1.92; 95% CI, 1.05-3.50) and FEV1 of less than 80% of predicted value but an FEV1/forced vital capacity ratio of greater than 0.70 (OR, 2.15; 95% CI, 0.91-5.09; P = .08). Although few CVD/stroke events occurred in male subjects with asthma, a significant interaction with atopic status was found (P = .05). Conclusions: Studies are required to elucidate how asthma exposes older women to excess macrovascular risk and prospectively determine the short-acting β2-agonist-related risk in persons without existing CVD. CVD risk in relation to atopic status of asthma also requires further investigation.

LanguageEnglish
JournalJournal of Allergy and Clinical Immunology
Volume123
Issue number1
DOIs
Publication statusPublished - 1 Jan 2009
Externally publishedYes

Keywords

  • Adrenergic β-agonists
  • asthma
  • cardiovascular system
  • epidemiology
  • lung diseases
  • obstructive

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

@article{212679cdf865461090d9c3a6acf32ecd,
title = "Cardiovascular disease risk associated with asthma and respiratory morbidity might be mediated by short-acting β2-agonists",
abstract = "Background: Studies examining the asthma-related risks of cardiovascular disease (CVD) events have generally used selected samples or did not control for the effects of β2-agonist use, itself associated with CVD events. Objectives: We assessed the relationship between incident CVD/stroke and asthma and the effect of atopy while controlling for β2-agonist use in a representative adult population cohort free of CVD at baseline. Methods: The North West Adelaide Health Study (stage 1, n = 3812; stage 2, n = 3113) assessed spirometry, anthropometry, atopy, blood pressure, and lipid levels. Questionnaires assessed doctor-diagnosed asthma and CVD (myocardial infarction and angina)/stroke, smoking status, and demographics. Asthma was defined by self-report or FEV1 reversibility. Current short- and long-acting β2-agonist use was identified at follow-up. Results: Results are expressed as odds ratios (ORs) and 95{\%} CIs. By using multivariable logistic regression, after adjustment for risk factors, in female subjects incident CVD/stroke events were associated with asthma (OR, 3.24; 95{\%} CI, 1.55-6.78), with no effect modification by atopy (P for interaction = .61), and with as-required short-acting β2-agonist use (OR, 2.66; 95{\%} CI, 1.06-6.61). In male subjects events were associated with daily cough/sputum (OR, 1.92; 95{\%} CI, 1.05-3.50) and FEV1 of less than 80{\%} of predicted value but an FEV1/forced vital capacity ratio of greater than 0.70 (OR, 2.15; 95{\%} CI, 0.91-5.09; P = .08). Although few CVD/stroke events occurred in male subjects with asthma, a significant interaction with atopic status was found (P = .05). Conclusions: Studies are required to elucidate how asthma exposes older women to excess macrovascular risk and prospectively determine the short-acting β2-agonist-related risk in persons without existing CVD. CVD risk in relation to atopic status of asthma also requires further investigation.",
keywords = "Adrenergic β-agonists, asthma, cardiovascular system, epidemiology, lung diseases, obstructive",
author = "Sarah Appleton and Ruffin, {Richard E.} and Wilson, {David H.} and Anne Taylor and Robert Adams",
year = "2009",
month = "1",
day = "1",
doi = "10.1016/j.jaci.2008.10.032",
language = "English",
volume = "123",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Cardiovascular disease risk associated with asthma and respiratory morbidity might be mediated by short-acting β2-agonists

AU - Appleton, Sarah

AU - Ruffin, Richard E.

AU - Wilson, David H.

AU - Taylor, Anne

AU - Adams, Robert

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Background: Studies examining the asthma-related risks of cardiovascular disease (CVD) events have generally used selected samples or did not control for the effects of β2-agonist use, itself associated with CVD events. Objectives: We assessed the relationship between incident CVD/stroke and asthma and the effect of atopy while controlling for β2-agonist use in a representative adult population cohort free of CVD at baseline. Methods: The North West Adelaide Health Study (stage 1, n = 3812; stage 2, n = 3113) assessed spirometry, anthropometry, atopy, blood pressure, and lipid levels. Questionnaires assessed doctor-diagnosed asthma and CVD (myocardial infarction and angina)/stroke, smoking status, and demographics. Asthma was defined by self-report or FEV1 reversibility. Current short- and long-acting β2-agonist use was identified at follow-up. Results: Results are expressed as odds ratios (ORs) and 95% CIs. By using multivariable logistic regression, after adjustment for risk factors, in female subjects incident CVD/stroke events were associated with asthma (OR, 3.24; 95% CI, 1.55-6.78), with no effect modification by atopy (P for interaction = .61), and with as-required short-acting β2-agonist use (OR, 2.66; 95% CI, 1.06-6.61). In male subjects events were associated with daily cough/sputum (OR, 1.92; 95% CI, 1.05-3.50) and FEV1 of less than 80% of predicted value but an FEV1/forced vital capacity ratio of greater than 0.70 (OR, 2.15; 95% CI, 0.91-5.09; P = .08). Although few CVD/stroke events occurred in male subjects with asthma, a significant interaction with atopic status was found (P = .05). Conclusions: Studies are required to elucidate how asthma exposes older women to excess macrovascular risk and prospectively determine the short-acting β2-agonist-related risk in persons without existing CVD. CVD risk in relation to atopic status of asthma also requires further investigation.

AB - Background: Studies examining the asthma-related risks of cardiovascular disease (CVD) events have generally used selected samples or did not control for the effects of β2-agonist use, itself associated with CVD events. Objectives: We assessed the relationship between incident CVD/stroke and asthma and the effect of atopy while controlling for β2-agonist use in a representative adult population cohort free of CVD at baseline. Methods: The North West Adelaide Health Study (stage 1, n = 3812; stage 2, n = 3113) assessed spirometry, anthropometry, atopy, blood pressure, and lipid levels. Questionnaires assessed doctor-diagnosed asthma and CVD (myocardial infarction and angina)/stroke, smoking status, and demographics. Asthma was defined by self-report or FEV1 reversibility. Current short- and long-acting β2-agonist use was identified at follow-up. Results: Results are expressed as odds ratios (ORs) and 95% CIs. By using multivariable logistic regression, after adjustment for risk factors, in female subjects incident CVD/stroke events were associated with asthma (OR, 3.24; 95% CI, 1.55-6.78), with no effect modification by atopy (P for interaction = .61), and with as-required short-acting β2-agonist use (OR, 2.66; 95% CI, 1.06-6.61). In male subjects events were associated with daily cough/sputum (OR, 1.92; 95% CI, 1.05-3.50) and FEV1 of less than 80% of predicted value but an FEV1/forced vital capacity ratio of greater than 0.70 (OR, 2.15; 95% CI, 0.91-5.09; P = .08). Although few CVD/stroke events occurred in male subjects with asthma, a significant interaction with atopic status was found (P = .05). Conclusions: Studies are required to elucidate how asthma exposes older women to excess macrovascular risk and prospectively determine the short-acting β2-agonist-related risk in persons without existing CVD. CVD risk in relation to atopic status of asthma also requires further investigation.

KW - Adrenergic β-agonists

KW - asthma

KW - cardiovascular system

KW - epidemiology

KW - lung diseases

KW - obstructive

UR - http://www.scopus.com/inward/record.url?scp=58149119494&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2008.10.032

DO - 10.1016/j.jaci.2008.10.032

M3 - Article

VL - 123

JO - Journal of Allergy and Clinical Immunology

T2 - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 1

ER -